<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04260789</url>
  </required_header>
  <id_info>
    <org_study_id>CP015</org_study_id>
    <nct_id>NCT04260789</nct_id>
  </id_info>
  <brief_title>Reduction of Pathogen Load From the Blood in Septic Patients With Suspected, Life-threatening Bloodstream Infection</brief_title>
  <official_title>Safety and Performance Evaluation of Seraph 100 Microbind Affinity Blood Filter (Seraph 100) in the Reduction of Pathogen Load From the Blood in Septic Patients With Suspected, Life-threatening Bloodstream Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ExThera Medical Europe BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ExThera Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vivantes Klinikum Neukölln</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ExThera Medical Europe BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and Performance Evaluation of Seraph 100 Microbind Affinity Blood Filter (Seraph 100)&#xD;
      in the reduction of pathogen load from the blood in septic patients with suspected,&#xD;
      life-threatening bloodstream infection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the lack of effective antibiotics for many bloodstream infections, and limited new&#xD;
      anti-infectives in development, there is a significant unmet need for new approaches that can&#xD;
      help treat drug-resistant infections, especially in patients at high risk. There is an unmet&#xD;
      need for a safe and broad-spectrum hemoperfusion therapy that can quickly reduce bacterial&#xD;
      load and shorten the duration of bacteremia, preferably without the need to first identifying&#xD;
      the type of bacteria present in the blood. There is an emerging need to increase the efficacy&#xD;
      of effective antibiotics, e.g., by using hemadsorption as adjunctive therapy, to by quickly&#xD;
      reducing bacterial load while scavenging toxins released from bacteria. Finally, there is a&#xD;
      medical growing need for an alternative therapy when no effective antibiotic is available.&#xD;
&#xD;
      Seraph 100 Microbind Affinity Blood Filter is used to reduce pathogen load during bloodstream&#xD;
      infection. Bacteremia or bloodstream infection, also called BSI, occurs when a bacterial&#xD;
      infection elsewhere in the body enters the bloodstream. This clinical condition can quickly&#xD;
      become life-threatening and progress to sepsis. Sepsis is defined as life-threatening organ&#xD;
      dysfunction caused by a dysregulated host response to infection (Singer et al., 2016).When&#xD;
      sepsis occurs with extremely low blood pressure, it's called septic shock. Septic shock is&#xD;
      fatal in many cases.&#xD;
&#xD;
      Sepsis can be triggered by many types of bacteremia although the exact source of the&#xD;
      infection often cannot be determined. Some of the most common infections that lead to BSI are&#xD;
      lung infections (i.e. pneumonia) and infections in the abdominal area. Patients who are&#xD;
      already in the hospital for something else, such as a surgery, are at a higher risk of&#xD;
      developing BSI. These infections are even more dangerous when the bacteria are already&#xD;
      resistant to antibiotics. The National Institutes of Health (NIH) estimates that over 1&#xD;
      million Americans get sepsis each year. Between 28 and 50 percent of these patients may die&#xD;
      from the condition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open randomized post-market trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of pathogens load</measure>
    <time_frame>4,5 hours +/- 30 min</time_frame>
    <description>Reduction of pathogens load from the bloodstream during treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>90 days</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence/Recurrence of bacteremia</measure>
    <time_frame>Day 1, day 2, day 7</time_frame>
    <description>Measure persistence recurrence of bacteremia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence/Recurrence of sepsis</measure>
    <time_frame>Daily during ICU stay or at least day 1, day 2, day 7</time_frame>
    <description>Measure persistence recurrence of sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ dysfunction-free days</measure>
    <time_frame>Daily during ICU stay or at least day 1, day 2, day 7</time_frame>
    <description>Measure organ dysfunction free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Intensive Care Unit (ICU) complications</measure>
    <time_frame>Daily during ICU stay or at least day 1, day 2, day 7</time_frame>
    <description>Reduction of ICU complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days (VFDs)</measure>
    <time_frame>Daily during ICU stay or at least day 1, day 2, day 7</time_frame>
    <description>VFD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay (LOS) at ICU and hospital ward</measure>
    <time_frame>During ICU and hospital ward stay or at least day 1, day 2, day 7</time_frame>
    <description>Measure LOS</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Treatment emergent adverse events</measure>
    <time_frame>Occurrence within the 90 days follow-up period</time_frame>
    <description>N (%) of patients with treatment emergent adverse events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">232</enrollment>
  <condition>Bloodstream Infection</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment with Seraph Filter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Seraph 100,The Microbind Affinity Blood Filter</intervention_name>
    <description>Treatment with Seraph 100 in one arm</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with sepsis and suspected bloodstream infection&#xD;
&#xD;
          2. Be ≥ 18 years old and ≤ 90 years old&#xD;
&#xD;
          3. Adults receiving IV antibiotic therapy&#xD;
&#xD;
          4. Increase of at least two points of the Sequential Organ Failure Assessment (SOFA)&#xD;
             score&#xD;
&#xD;
          5. Subjects that presents Procalcitonin (PCT) levels &gt; 0,5 ng/mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is currently participating in another clinical investigation&#xD;
&#xD;
          2. Pregnant or nursing subjects and those who plan pregnancy during the clinical&#xD;
             investigation follow-up period&#xD;
&#xD;
          3. Presence of comorbid conditions, or other medical, social, or psychological conditions&#xD;
             that, in the investigator's opinion, could limit the subject's ability to participate&#xD;
             in the clinical investigation or to comply with follow-up requirements, or impact the&#xD;
             scientific soundness of the clinical investigation results&#xD;
&#xD;
          4. The first dose of the current antibiotic therapy was &gt; 24 h before screening&#xD;
&#xD;
          5. Have Child-Pugh Class C cirrhosis&#xD;
&#xD;
          6. Have platelet count &lt; 30.000/uL&#xD;
&#xD;
          7. Contraindications for heparin sodium for injection&#xD;
&#xD;
          8. Subjects demonstrating any contraindication for this treatment as described in the IFU&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herwig Gerlach, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vivantes Klinikum Neukölln</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carla Kikken-Jussen</last_name>
    <phone>+31438200399</phone>
    <email>carla@extheramedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Middelheim Hospital</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Bocage Central</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Rimmelé, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Rimmelé, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nouvel Hopital Civil</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Aschaffenburg-Alzenau</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Braunschweig GmbH</name>
      <address>
        <city>Braunschweig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Kielstein, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Jan Kielstein, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universität Witten-Herdecke</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Achim Jörres, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Achim Jörres, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen (AöR)</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bartosz Tyczynski, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Bartosz Tyczynski, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Betz, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Christoph Betz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Greifswald</name>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asklepios Hospital St. Georg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Berthold Bein, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Berthold Bein, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universität Rostock</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steffen Mitzner, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Steffen Mitzner, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Usl Toscana Centro</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital, Pisa</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Forfori, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Forfori, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.Gemelli University Hospital</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Gelderse Vallei</name>
      <address>
        <city>Ede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jagiellonia University</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Surrey NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lui Forni, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Lui Forni, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

